GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

CARsgen Therapeutics Holdings 2171.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

11.22

+3.03%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥146.3m

FY2019FY2025

Net income

−CN¥113.9m

FY2019FY2025

Free cash flow

−CN¥282.9m

FY2019FY2025

Shareholders' equity

CN¥912.2m

FY2019FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
RevenueCN¥146.3mCN¥39.4m——CN¥30.0m——
Research and developmentCN¥285.6mCN¥466.2mCN¥661.7mCN¥791.9mCN¥584.0mCN¥328.0mCN¥244.7m
Operating income−CN¥121.3m−CN¥808.2m−CN¥767.6m−CN¥1.03bn−CN¥668.0m−CN¥380.7m−CN¥264.7m
Net income−CN¥113.9m−CN¥798.1m−CN¥747.8m−CN¥1.04bn−CN¥5.52bn−CN¥1.24bn−CN¥308.6m
Diluted earnings per share-0.21-1.44-1.34-1.88-10.03-6.25-5.44

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Total assetsCN¥1.50bnCN¥1.95bnCN¥2.26bnCN¥3.22bnCN¥4.08bnCN¥1.46bnCN¥379.2m
Cash and short-term investmentsCN¥1.31bnCN¥1.72bnCN¥1.85bnCN¥2.64bnCN¥3.50bnCN¥1.21bnCN¥112.3m
Total liabilitiesCN¥597.2mCN¥717.4mCN¥455.5mCN¥337.2mCN¥592.5mCN¥3.41bnCN¥1.23bn
DebtCN¥86.2mCN¥166.4mCN¥85.2mCN¥119.4mCN¥338.0mCN¥100.3mCN¥51.3m
Shareholders' equityCN¥912.2mCN¥1.23bnCN¥1.80bnCN¥2.88bnCN¥3.49bn−CN¥1.95bn−CN¥852.8m
Shares outstanding553m553m557m554m550m198m57m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations−CN¥275.8m−CN¥409.7m−CN¥529.6m−CN¥748.5m−CN¥596.3m−CN¥343.6m−CN¥208.4m
Capital spending−CN¥7.1m−CN¥19.6m−CN¥11.1m−CN¥161.3m−CN¥207.7m−CN¥21.8m−CN¥120.4m
Free cash flow−CN¥282.9m−CN¥429.3m−CN¥540.7m−CN¥909.9m−CN¥804.1m−CN¥365.4m−CN¥328.8m

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Sept 2023Jun 2023
RevenueCN¥71.1mCN¥87.0mCN¥59.3mCN¥19.7mCN¥19.7m———
Operating income−CN¥157.5m−CN¥32.0m−CN¥89.3m−CN¥404.1m−CN¥404.1m−CN¥767.5m−CN¥238,820−CN¥218,081
Net income−CN¥76.5m−CN¥26.0m−CN¥87.9m−CN¥399.1m−CN¥399.1m−CN¥171,661−CN¥199,816−CN¥235,405
Diluted earnings per share-0.14-0.05-0.16-0.72-0.72-0.00-0.00-0.00
Cash from operations—−CN¥55.0m−CN¥240.0m−CN¥153.0m−CN¥308.0m———
Capital spending—−CN¥55.0m−CN¥2.0m−CN¥4.0m−CN¥5.0m———
Free cash flow—−CN¥110.0m−CN¥242.0m−CN¥157.0m−CN¥313.0m———
Total assetsCN¥1.84bnCN¥1.50bnCN¥1.76bnCN¥1.67bnCN¥2.10bnCN¥2.26bnCN¥2.63bnCN¥3.08bn
Cash and short-term investmentsCN¥1.63bnCN¥1.31bnCN¥1.47bnCN¥1.48bnCN¥1.65bnCN¥1.85bnCN¥2.15bnCN¥2.53bn
DebtCN¥34.8mCN¥86.2mCN¥119.5mCN¥166.4mCN¥213.1mCN¥85.2mCN¥17.2mCN¥129.3m
Shareholders' equityCN¥1.27bnCN¥912.2mCN¥1.12bnCN¥1.06bnCN¥1.50bnCN¥1.80bnCN¥2.10bnCN¥2.57bn

Financial ratios

Data as of 9 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Operating margin-181.4%-1426.0%——-2275.6%—
Net margin-77.9%-2024.4%——-18380.0%—
Return on equity-12.5%-75.5%-41.5%-36.1%-158.3%63.5%
Return on assets-7.6%-47.7%-33.1%-32.3%-135.3%-84.9%
Free cash flow yield-3.6%-6.1%-6.9%-7.8%-5.2%-12.0%
Revenue growth218.7%—————
Earnings growth-87.7%6.7%-16.2%-81.2%345.9%301.3%
Current ratio5.73x6.02x9.55x13.45x7.89x7.27x
Debt to equity0.03x0.10x0.01x0.01x0.08x-0.05x
Equity ratio60.6%63.2%79.8%89.5%85.5%-133.7%
Interest coverage-33.04x-98.41x-168.32x-51.91x-54.04x-27.42x
R&D as a share of sales195.3%1182.5%——1943.7%—
Buybacks as a share of market value0.0%0.7%-0.5%-0.6%-177.8%—

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-50.9%-20.4%—
Net income-52.1%-38.0%—

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-500.5%———
Net margin-491.1%———

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings-61.7-5.5-4.2-6.9-2.4
Price to sales48.1112.2——436.4

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.